Bone Health And Diabetes Management

Diabetes’s not going away; we all know someone with the condition, as the rates continue to rise, with one in twenty (5.3%) people diagnosed with diabetes in 2020-21.

Did you know?

  • The rates of diabetes diagnosis were similar for males and females (5.7% and 4.9%)
  • The rate of diabetes increased with age from 10.3% for people aged 55-64 years to 14.9% for people aged 65-74 years
  • Almost one in five (19.2%) people over 75 had diabetes.

Type 2 diabetes is the most common type of diabetes (85.5%), followed by Type 1 diabetes (11.0%), and 4.1% was not reported (excluding gestational diabetes). (Australian Bureau of Statistics, 2021)

For us at OsteoStrong, we are aware of the impacts this condition has on multiple systems of the body, including quality of life and potentially reducing life expectancy. The intricacies of interaction and communication between the bone and muscle systems with the hormonal system is not something to be ignored, and we are always looking for opportunities to highlight the need to prevent bone and muscle loss.

For individuals with Type 1 Diabetes, the diagnosis usually occurs at a young age, impacting the potential for high peak bone mass, maximum strength, and density. Bone development features highly between the ages of 13 and 19 years, and peaks are usually reached by 30 years old. The use of insulin contributes to higher fracture risk. The mechanism seems to point to defects in the body’s bone-building cells and their ability to differentiate.

The chronic metabolic deconditioning of individuals with Type 2 diabetes adds complications such as nerve damage, muscle weakness, episodes of low blood sugar and vision problems increasing the risk of falls and fractures. This is usually attributed to an increase in bone reabsorption parameters.

Treatment of diabetes aims to prevent complications by controlling blood glucose (HBA1C) levels and helping insulin work more effectively. More than three quarters (76.1%) of people with diabetes took one or more actions to manage their condition:

  • One in five (22.3%) took insulin daily
  • More than six in ten (63.7%) changed their eating pattern or diet
  • Three in ten (31.9%) exercised most days
  • One in ten (10.9%) were not taking current action to manage their diabetes.

That, combined with aging-related muscle loss and strength, leads to deconditioning and loss of the very structures we need to regulate our muscles, bones, and hormones.

But here’s something you might not know, as an individual physical modality, OsteoStrong has been shown to perform positively in reducing HBA1C and long-term blood glucose measures compared to the standard care modalities when reviewed independently. And that’s something that should matter to all of us, whether we’ve been diagnosed with a metabolic disorder or not

How does osteogenic loading impact blood glucose? Osteogenic loading can trigger osteogenesis or the growth of bone tissue. Research shows that it can also trigger myofibril hypertrophy. Myofibril hypertrophy increases the number of myofibrils–bundles of muscle fibers–within the muscle cells. This, in turn, increases muscle density.

Osteogenic loading fatigues muscle cells, which causes muscle density to increase. This fatigue isn’t related to fuel; it’s a fatigue of the structure within the muscle cells. As this contraction continues, the nervous system undergoes a structural deficit. This stimulates an adaptation and triggers the building of new myofibrils, bundles of fibers within a muscle.

These myofibrils provide new insulin receptors within the cells. This, in turn, lowers resting blood glucose levels. With this change, the body can process blood glucose to a higher degree—improving the condition of people with metabolic disease.

Through research, it’s been shown that 58 percent of cases of Type 2 diabetes can be prevented or delayed by maintaining a healthy weight, being physically active and applying the “use it or lose it” principle.

Osteogenic loading therapy is a confirmed modality to support standard care, being both feasible and effective in improving glycaemic control among moderate-risk adults with poor glycaemic control. Just ask many of our members who have seen improvements in their blood glucose levels, strength and density.

Team OsteoStrong

Team OsteoStrong